|
Jan Marini Skin Research Suspends Sales of Popular Eyelash Products
SAN JOSE, Calif., Jan. 17 /PRNewswire/ -- Jan Marini Skin Research, Inc. (JMSR; http://www.janmarini.com) today announced that it will voluntarily suspend the sale of its Age Intervention Eyelash Conditioner and Age Intervention Masses of Lashes Mascara products in the U.S. JMSR cited a patent infringement lawsuit by Allergan Pharmaceutical as one reason for the suspension. "We believe that it makes sense to suspend these products while we strategically review our options," said JMSR President & CEO Jan Marini. "We are assured that the Allergan allegations are unfounded. However, the lawsuit is a major distraction." JMSR reasserted its confidence in the safety profile of the products, and noted that it has conducted numerous and excellent safety studies. The company maintains its legal right to market both products.
Drug Treatment
Corticosteroids (commonly called steroids) are mainstay treatments for acute relapses patients with relapse-remitting MS. High-dose methylprednisolone given intravenously (IVMP) is typically administered for major relapse, often followed by oral prednisone for a few days. Steroids reduce inflammation in the central nervous system and may help suppress the immune system's attack on myelin and even improve electrical conduction. Steroids, in general, do not improve the long-term course of the disease and can lose effectiveness if overused. They are not generally used for maintenance therapy. Some research, however, is reporting benefits from the use of pulsed administration of intravenous methylprednisolone. Such an approach typically administers the steroid daily for 5 days every 4 months for 3 years, then every 6 months for 2 years.
As Windows Server 2008 RTMs, Customers and Partners Adopting with Help ...
REDMOND, Wash., Feb. 4, 2008 –Approaching the company's largest enterprise launch in its history, Microsoft reached another important milestone today with the release to manufacturing (RTM) of Windows Server 2008. The response from IT professionals and developers has been strong as the company moves toward the worldwide launch of Windows Server 2008, SQL Server 2008 and Visual Studio 2008 on February 27. One indication of the momentum that is building around the latest server operating system is the number of beta and evaluation versions that customers and partners have obtained: more than two million. IT professionals face increasing pressure from rapidly changing technology, increasing costs and security concerns, and expanding business needs. Windows Server 2008 helps alleviate these pressures by automating daily management tasks, tightening security, improving efficiency and increasing availability.
New Study Shows Isolaz Can Reduce Acne Up to 90 Percent
SANTA MONICA, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Southern California-based dermatologist Ava Shamban, MD and co-investigators Mikiko Enokibori, MD, and Vic Narurkar, MD, conducted a global multi-center study using Isolaz to treat patients suffering from various degrees of acne, ranging from mild and moderate inflammatory acne to severe nodular and cystic acne. The February edition of the Journal of Drugs in Dermatology will report the results of this study using the Isolaz device (Aesthera Corp(TM), Pleasanton, CA) for the treatment of mild to severe acne. Prospective and retrospective data was collected from 56 patients who had undergone two to four treatments with a photopneumatic device (Isolaz). Evaluation criteria included lesion counts, using blinded physician evaluations of acne clearance, as well as treatment satisfaction surveys given to the participating physicians and patients.
|
